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 Sirs, 
We read with interest the recent meta-analysis by Swaminath et al (2017) that reviewed studies on 
induction of remission with exclusive enteral nutrition (EEN) in paediatric Crohn’s disease (CD)1. 
We feel however that the title of the article is slightly misleading as the authors only include studies 
that directly compare the efficacy of EEN against corticosteroids (CS), excluding other studies where 
EEN was used, without a direct comparator arm with CS (table 2, page 1) excluding also points of 
secondary analysis like faecal calprotectin (FC). 
We were encouraged to note the authors describe EEN to be as efficacious as CS, as shown in the 
previous AP&T meta-analysis; with the advantage of superior outcomes in terms of mucosal 
healing2. 
We are aware that FC associates with rates of mucosal healing 3. Therefore, it seemed paradoxical to 
us that there was no difference in FC levels between EEN and CS, despite the significant differences 
in mucosal healing rates. We looked for the FC data mentioned but found no evidence of the studies 
from which the abstract data was generated. 
We performed our own literature search specifically for studies reporting changes to FC levels during 
EEN, independent of the necessity including a CS arm. From an initial search using MEDLINE with the 
term “Exclusive enteral nutrition AND Crohn’s” we identified and reviewed 181 abstracts and were 
left with 18 relevant studies, including five studies from overlapping patient cohorts4–10. To prevent 
duplication of results, only one study from the group were considered for the analysis. Using the 
mean or median FC as values presented from each study, we calculated the percentage decrease 
during the course of EEN and found that on average FC drops 48% on completion of an EEN course 
(figure 1 A and B).  
 
 
Figure 1: A) Mean/median faecal calprotectin of each study at treatment initiation and treatment end. B) The percentage 
decrease in faecal calprotectin  from treatment initiation and end of EEN 
All studies except Dunn et al report a significant decrease in FC concentration while on EEN. This 
study reports FC as binary < or > 250 μg/g. This may mask significant reductions in FC during EEN, 
that remains above normal reference values. We identified only one study with paired longitudinal 
endoscopic mucosal healing and FC data. However, the analysis performed in this study combined 
patients treated with either EEN or CS. As they did not distinguish the treatment arms of the patients 
it was removed from our analysis 11. 
While the exact mechanisms by which EEN works, and drives FC reduction, remain elusive; the gut 
microbiota plays a pivotal role9,12. 
It is well known that the composition and metabolic activity of the microbiota is altered during EEN. 
The study from our group, Quince et al (2015), collected serial faecal samples and by using stepwise 
regression, we identified 14 operational taxonomic units that predicted 78% of the variation to FC. 
This study and others have shown that EEN substantially modulates the microbiota, by reducing 
bacterial diversity, altering the relative abundance of metabolic pathways while altering the local 
microenvironment and major bacterial metabolites. We suspect these mechanisms by extension 
would be important in the process of mucosal healing too although specific studies addressing this 
are needed. 
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